- Poster #5915: Three-dimensional (3-D) Multiplex Imaging of Biomarkers in Tumor Tissue
(posted: Apr, 2017)
Clearlight presented research data at the 2017 American Association for Cancer Research (AACR) annual meeting. Includes a link to the poster with the full presentation.
- ClearLight Presents Data on the Multiplex 3D Imaging of the Tumor Microenvironment
(posted: Mar, 2017)
ClearLight announced today that it will present data at the 2017 American Association for Cancer Research meeting in Washington DC on Wednesday, April 5, 2017, 8:00 AM-12:00 PM in the Convention Center Halls A-C, poster session 43, board number 27.
- ClearLight Diagnostics Raises $3.5M in Series B Funding
(posted: Dec, 2016)
Clearlight has completed a $3.5M Series B financing round. The financing will go towards the continued technology platform and applications development using the CLARITY technology and deep imaging with COLM Light Sheet Microscopy.
ClearLight Diagnostics Announces the Appointment of Sarah McCurdy, MBA as its Chief Executive Officer
posted: May 1st, 2015
PALO ALTO, Calif., May 1, 2015 - ClearLight Diagnostics, LLC (ClearLight), an early stage, start up company pursuing new technologies for next generation tissue processing and 3D imaging platforms, announced today the appointment of Sarah McCurdy, MBA as Chief Executive Officer. Ms. McCurdy will serve as a Board Member to the company as well.
"Ms. McCurdy brings a broad skill set and experience from both a scientific and business perspective. She has had a long career contributing to product development and global commercialization within a startup framework, as well as established companies in the biotechnology and medical device sectors. We are very excited to have Sarah on board and we are confident that she will provide the key leadership that is needed to develop and commercialize this platform", said Alex Wiegers of Wiegers Capital.
Prior to joining ClearLight, Ms. McCurdy held Business Leadership positions at W.L. Gore & Associates, A Global Medical Device manufacturer located in Flagstaff, Arizona. She also held positions of increasing responsibility at Applied Biosystems, Gilead Sciences and Lynx Therapeutics.
ClearLight is developing a tissue processing platform based on the CLARITY lipid-clearing technique developed by Karl Deisseroth M.D., Ph.D. and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. This process produces fully assembled intact tissue, which is optically transparent and permeable to macromolecules, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment. This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy), will enable unprecedented depth and acceleration of image collection from lipid-cleared samples interrogated with biomolecules.
About ClearLight Diagnostics
ClearLight Diagnostics is a technology development company focused on the discovery, development and commercialization of innovative technologies to significantly improve the diagnosis and treatment of a wide range of diseases. The company is developing a groundbreaking tissue processing and imaging platform that allows for the three-dimensional investigation of molecular and structural information within specific tissues. The CLARITY method is built on sophisticated chemical treatments of tissues to make them fully transparent and includes COLM, a powerful imaging platform that allows for visualization of labeled tissue elements, cells and connections within tissue blocks.
For immediate release: Clearlight Diagnostics, Inc.